The Aerobika(R) Device, Marketed by Monaghan Medical in the United States, Benefits COPD Patients and Wins Gold at MDEA Awards

PLATTSBURGH, NY--(Marketwired - Jul 16, 2014) - The Aerobika® Oscillating Positive Expiratory Pressure (OPEP) Therapy System marketed by Monaghan Medical Corporation has earned Gold at the Medical Design Excellence Awards (MDEA). MDEA is an International Award recognizing groundbreaking products that save lives, improve patient healthcare, change the face of medical technology, and overcome design and engineering challenges. It is one of the medical technology industry's highest honors.

The Aerobika® Oscillating PEP device is a drug-free, easy to use, hand-held device that helps people with COPD, Cystic Fibrosis (CF) and other respiratory conditions to breathe easier and live better. COPD (Chronic Obstructive Pulmonary Disease) is the fourth leading cause of death globally and continues to grow in prevalence. Clinical evaluations conducted at Robarts Research Institute (Western University, London) demonstrated use of the device could significantly reduce breathlessness and improve patient's quality of life.

"When the Aerobika® Oscillating PEP Therapy System was created, the goal was to develop a product that addressed an unmet need for patients suffering from serious respiratory conditions, including COPD, CF, Bronchiectasis, Post Op and any patient with a productive cough requiring a non - pharmaceutical method to assist removing secretions from the lung. The innovation built into the Aerobika® OPEP device delivers excellent effectiveness while being very easy to use," states Dom Coppolo, Vice President of Clinical Affairs at Monaghan Medical Corporation. "The overall goal of the device is to ensure the patient can maintain their treatments to control their symptoms, breathe easier, enjoy a better quality of life and ultimately, stay out of the hospital."

The award was announced at the MDEA Awards Ceremony held on Wednesday, June 11, 2014 in New York City. Entries were evaluated by an impartial panel of industry experts comprised of practicing doctors, nurses, and technicians alongside industrial designers, engineers, manufacturers, and human factors experts. The Aerobika® Oscillating PEP device was deemed to excel in 5 evaluation criteria: manufacturing and technological innovation; design and engineering advancements; patient benefits; business benefits; and overall improvement to healthcare industry.

The Aerobika® Oscillating PEP device is available at many leading hospitals across the United States and by prescription from a physician. The Aerobika® Oscillating PEP device is marketed by Monaghan Medical Corporation in the United States. For more information about this story as well as image and video downloads, please visit: http://www.monaghanmed.com/news/aerobika-device-marketed-monaghan-medical-united-states-benefits-copd-patients-and-wins-gold-md

About Monaghan Medical Corporation
Monaghan Medical Corporation (MMC), headquartered in Plattsburgh, New York (USA), is a leader in the development, manufacture and/or marketing of respiratory devices in the United States, such as the flagship AeroChamber® Brand of Valved Holding Chamber (VHC) for asthma patients. Its best-in-class respiratory management products are developed and validated at its affiliate's world-renowned Aerosol Lab. The respiratory management products it markets today and has marketed in the past in the United States are the subject of peer reviewed articles published in various medical journals, such as the New England Journal of Medicine, CHEST.